levodopa has been researched along with 3,9-bis((ethylthio)methyl)-k-252a in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Standaert, DG; Yacoubian, TA | 1 |
| Murata, M | 1 |
2 review(s) available for levodopa and 3,9-bis((ethylthio)methyl)-k-252a
| Article | Year |
|---|---|
Targets for neuroprotection in Parkinson's disease.
Topics: Animals; Antioxidants; Antiparkinson Agents; Carbazoles; Clinical Trials as Topic; Dopamine Agonists; Humans; Levodopa; Nerve Growth Factors; Neuroprotective Agents; Oxepins; Parkinson Disease | 2009 |
[Therapy of Parkinson's disease--up to date].
Topics: Anticonvulsants; Antiparkinson Agents; Carbazoles; Dopamine Agents; Dopamine Agonists; Drug Design; Genetic Therapy; Humans; Isoxazoles; Levodopa; Neuroprotective Agents; Parkinson Disease; Randomized Controlled Trials as Topic; Substantia Nigra; Zonisamide | 2008 |
1 trial(s) available for levodopa and 3,9-bis((ethylthio)methyl)-k-252a
| Article | Year |
|---|---|
The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD.
Topics: Aged; Antiparkinson Agents; Area Under Curve; Carbazoles; Diarrhea; Double-Blind Method; Female; Humans; Indoles; Levodopa; Male; Middle Aged; Parkinson Disease; Protein Kinase Inhibitors; Treatment Outcome | 2004 |